$PFE Recent Headlines Pfizer drops 2.5% to lead Dow

New Post Public Reply Private Reply Replies (0) Message Board

Apr 7, 2014 at 10:12 AM

$PFE Recent Headlines

Pfizer drops 2.5% to lead Dow decliners 36 min ago - William L. Watts
Questcor surges on buyout; MannKind sinks 8:28 a.m. Today - Ben Eisen
How sector stock funds can make your portfolio whole 7:01 a.m. Today - Jonathan Burton
Best, worst stocks of the $100 billion club: Morgan Stanley 2:03 p.m. March 31, 2014 - blogs.marketwatch.com
Pfizer anti-cholesterol drug meets main study goal 9:28 a.m. March 27, 2014 - MarketWatch.com
Apple looks ready to head higher 3:48 p.m. March 17, 2014 - blogs.marketwatch.com
Apple as the Comeback Kid 1:13 p.m. March 13, 2014 - Mark Hulbert
Mylan to start selling generic Celebrex in May 7:22 a.m. March 13, 2014 - MarketWatch.com
Pfizer loses Celebrex patent ruling; shares halted but effect muted 3:21 p.m. March 12, 2014 - blogs.marketwatch.com
Pfizer loses ruling on Celebrex patent dispute 2:46 p.m. March 12, 2014 - Russ Britt
Trading resumes on Pfizer shares 2:37 p.m. March 12, 2014 - Russ Britt
Ruling invalidates Pfizer's Celebrex patent 2:36 p.m. March 12, 2014 - Russ Britt
Pfizer obtained reissue patent on Celebrex in 2013 2:35 p.m. March 12, 2014 - Russ Britt
Pfizer plans to appeal ruling on Celebrex judgment 2:31 p.m. March 12, 2014 - Russ Britt
Pfizer loses ruling on Celebrex patent dispute 2:30 p.m. March 12, 2014 - Russ Britt
Pfizer halted 2:15 p.m. March 12, 2014 - Steve Goldstein
S&P 500 extends the break to ‘clear skies’ territory 10:46 a.m. March 6, 2014 - Michael Ashbaugh
Newscast: Stocks take a spill to start the week 4:26 p.m. March 3, 2014 - MarketWatch
Pfizer aims to sell over-the-counter version of Lipitor 8:13 a.m. March 3, 2014 - Peter Loftus
Newscast: Pfizer moves to make Lipitor OTC 7:39 a.m. March 3, 2014 - MarketWatch

Does Pfizer Belong in Your Portfolio? 8:34 a.m. Today - Wall St. Cheat Sheet
Pre-Market Laggard: Pfizer (PFE) 7:44 a.m. Today - TheStreet.com
Wall Street Breakfast: Must-Know News 6:31 a.m. Today - Seeking Alpha
MNKD Stock, Take Two: Volatility or Not, You Have to Like Afrezza 4:36 a.m. Today - InvestorPlace.com
Pfizer drug helps stop progression of breast cancer 3:56 a.m. Today - Seeking Alpha
Choose Your Route to Sector Investing 4:00 p.m. April 6, 2014 - The Wall Street Journal Interactive Edition
Pfizer, Lilly Drugs Show Promise in Slowing Breast Cancer 10:47 a.m. April 6, 2014 - The Wall Street Journal Interactive Edition
Coping With Wall Street's Fickle Nature,Yellow Flag for the IPO Hoopla: Jim Cramer's Best Blogs 1:10 p.m. April 5, 2014 - TheStreet.com
Supreme Court Studies Generic Drug Question: How Will Patients Fare? 6:19 p.m. April 4, 2014 - Wall St. Cheat Sheet
Merck KGaA and Auxogyn Collaborate - Analyst Blog 5:00 p.m. April 4, 2014 - Zacks.com
3 Stocks Reiterated As A Buy: PFE, BMY, OXY 1:29 p.m. April 4, 2014 - TheStreet.com
Venture Capitalist Ran Nussbaum Brings Big Finance To Little Biotechs 8:31 a.m. April 4, 2014 - Seeking Alpha
Merck KGaA, Pfizer and Broad Institute Collaborate - Analyst Blog 5:10 p.m. April 3, 2014 - Zacks.com
The Dow Earnings Season Mega-Chart 4:14 p.m. April 3, 2014 - TheStreet.com
PFE May 23rd Options Begin Trading 11:15 a.m. April 3, 2014 - TheStreet.com
Danger Zone: Value Investors 9:16 a.m. April 3, 2014 - Seeking Alpha
Pfizer Inc (PFE): Today's Featured Drugs Winner 5:00 p.m. April 2, 2014 - TheStreet.com
China still bright for Big Pharma 11:30 a.m. April 2, 2014 - Seeking Alpha
Three Reasons to Be Cautious on Pfizer 10:02 a.m. April 2, 2014 - Barrons.com
Is It Too Early To Invest In Versartis? 9:08 a.m. April 2, 2014 - Seeking Alpha

NDA Filings, FDA Approvals, Executive Appointments, Ceased Clinical Trials, and Public Offerings - Analyst Notes on Johnson & Johnson, Pfizer, Merck, GSK, and Intercept 8:00 a.m. Today - PR Newswire - PRF
Pfizer’s Novel CDK 4/6 Inhibitor Palbociclib plus Letrozole Significantly Prolonged Progression-Free Survival in Patients with Advanced Breast Cancer 10:30 a.m. April 6, 2014 - BusinessWire - BZX
AMCP Foundation Launches Initiative to Identify Emerging Medication Management Practices that Can Advance Patient Care and Outcomes; Project Supported by Pfizer 12:38 p.m. April 3, 2014 - PR Newswire - PRF
Exosomes Shine a Light on Alzheimer's Disease and CTE 10:16 a.m. April 3, 2014 - ACCESSWIRE
Senior Notes Conversions, FDA Drug Approvals, Acquisitions, Stock Price Updates, and Clinical Trial Studies - Analyst Notes on Gilead, Pfizer, Nordion, Intuitive Surgical, and Novartis 8:00 a.m. April 3, 2014 - PR Newswire - PRF
ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool 2:30 p.m. April 1, 2014 - PR Newswire - PRF
LabCentral Announces Sponsorship by Pfizer to Support Life-Science Startup Companies in Cambridge, Massachusetts 8:30 a.m. April 1, 2014 - PR Newswire - PRF
Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium® 24HR 6:26 p.m. March 28, 2014 - BusinessWire - BZX
Technical Summary on Active Stocks -- Research on Cisco Systems, Pfizer, Vale, and Advanced Micro Devices 11:31 a.m. March 28, 2014 - PR Newswire - PRF
Positive Opinions, Presentation Schedules of Investigational Data, Clinical Study Results, and Stock Price Movements - Analyst Notes on Johnson & Johnson, Merck, Pfizer, Amgen, and Allergan 8:00 a.m. March 28, 2014 - PR Newswire - PRF
In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control 1 8:16 a.m. March 27, 2014 - BusinessWire - BZX
Bococizumab (RN316) Significantly Reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study1 8:02 a.m. March 27, 2014 - BusinessWire - BZX
Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN® In Very Young Children Born Small For Gestational Age 8:01 a.m. March 26, 2014 - BusinessWire - BZX
Pfizer Invites Public To View And Listen To Webcast Of May 5 Conference Call With Analysts 5:10 p.m. March 25, 2014 - BusinessWire - BZX
Pfizer Reports Positive Phase 3 Study Outcome Of XALKORI® (crizotinib) Compared To Chemotherapy In Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) 8:30 a.m. March 25, 2014 - BusinessWire - BZX
Renaissance Technologies Buys Stake in Pfizer; Yahoo Looks to Profit from Alibaba IPO 12:21 a.m. March 25, 2014 - ACCESSWIRE
Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL® in Adults with Moderate-to-Severe Chronic Plaque Psoriasis 11:45 a.m. March 22, 2014 - BusinessWire - BZX
Healthcare Companies Report Acquisitions, Upcoming Results Schedules, Dividends, and Annual Reviews - Analyst Notes on Pfizer, Magellan Health Services, Prothena, Alere, and KYTHERA 8:00 a.m. March 21, 2014 - PR Newswire - PRF
Pfizer’s Investigational Vaccine Candidate Bivalent rLP2086 Receives U.S. Food and Drug Administration Breakthrough Therapy Designation for Potential Prevention of Meningococcal B Disease 8:31 a.m. March 20, 2014 - BusinessWire - BZX
Healthcare Companies Report FDA Approvals, Comprehensive Analysis, Schedules, and Stock Movements - Analyst Notes on Pfizer, Johnson & Johnson, Biogen, Express Scripts, and Forest Laboratories 8:00 a.m. March 20, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BC Mosaic App Store Unlocks New Tools for Researchers

Unleashing Innovation Through Specialized Apps Oh boy, it's about time someone shook things up in the research game. BC Platforms has rolled out the BC Mosaic App Store, a move that's got research types buzzing from Zurich to... well, anywhere healthcare pokes its head. These guys aren't just throwing out some generic, run-of-the-mill tools. No sir, they've created a...

Broadridge Expands Tokenization with G7 Securities

Broadridge Takes a Big Step with G7 Integration Broadridge Financial Solutions is pulling no punches with its latest move—integrating G7 securities into its Distributed Ledger Repo (DLR) network. This isn't your average fintech maneuver; it's a heavyweight shift intended to redefine the way global financing and collateral markets work. Tokenized Repo: More Than Just a...

Skanska's $57M Deal to Transform Del Mar Traffic

A Roadway Overhaul in Del Mar A cool $57 million. That’s the ticket Skanska bought to scoop up the El Camino Real project in Del Mar, California. Think of it as a road facelift, a necessary one—it includes bulking up the corridor to four lanes and swapping in a spanking new San Dieguito River Bridge, taking the place of an old rascal that's been around for 84 years....

Fibocom's RU311: Navigating 5G's Mid-Tier Maze

Cracking Open the RU311 Phenomenon Technology must evolve with purpose. This time around, Fibocom's RU311 module series steps up to the plate, delivering a tailored solution in the 5G landscape for the mid-tier IoT devices that need more than just speed. Beyond Raw Bandwidth: What Really Matters Plenty of folks out there still chase the elusive thrill of higher speeds as...

Royal Mint Ventures Into the Final Frontier with Star Trek Coins

A Cosmic Coin Collection for the Ages The Royal Mint has stepped boldly into a realm where no coin has gone before—celebrating six decades of Star Trek with two new collectable 50p coins. For Star Trek fans who’ve followed the Enterprise to the furthest reaches of the galaxy, these coins aren’t just chump change—they’re keepsakes that capture a piece of sci-fi...

stackArmor Secures FedRAMP High: A Strategic Milestone

stackArmor: Carving a Niche in Federal Cybersecurity Hey, not every day you wake up to find a company carving its niche in federal cybersecurity quite the way stackArmor is doing. They've recently got their hands on that elusive FedRAMP High authorization for The Armory. What's this mean in English? Well, for starters, these guys are showing they're serious about...

BOC Group's Challenger Role Eye-Opener in Gartner Quadrant

Cracking the Challenger Code: BOC Group's Debut Ever heard of BOC Group? If you haven’t, it’s time to pay attention. This Dublin-based outfit just muscled its way into the Challenger Quadrant of the 2026 Gartner Magic Quadrant for Digital Twin of an Organization Platforms. Not bad for its first trip to the dance. When a company crashes the scene like this, eyebrows...

COFE Tech's $178M Pre-IPO Boost: Bold Move in MENA

COFE Tech's Pre-IPO Raise: Scoring Big Dollars Today I'm reading this deal 'bout COFE Tech, and let me tell ya, there's more to chew over than a bowl of oatmeal. They just wrapped up a pre-IPO round at a hefty $178 million valuation. This wasn't just any ol' investment — we're talking about Wa'ed Ventures, the venture arm of Aramco, along with some heavy-hitter partners...

Danielle D. Pollard Releases Game-Changing Exec Book

Revolutionizing Communication Dynamics In a world where every word is scrutinized, Danielle D. Pollard's new book, Act Like a Lady, Speak Like a Wolf, arrives like a jolt of caffeine on a sleepy morning. With decades of engineering know-how and corporate grit, Pollard serves up a no-frills strategy to conquer the communication game, especially designed for women fighting...

Veteran Suicide Prevention: The Urgency Behind CVN's Push

Veteran suicide is a crisis staring us square in the face, with rates 60% higher than the general population. It's a grim reminder that the mental toll on those who've served is a deep chasm hard to bridge. Cohen Veterans Network (CVN) is stepping up to the plate with a new campaign dubbed 'Ask Anyway: Conversations to Save a Life'. This isn't just any awareness...